Back to dashboard
CommercialCoverageLow impact

08.02.37, Eladocagene exuparvovec-tneq (Kebilidi™)

Independence Blue Cross·Oncology, Neurology, Pediatrics·Pharmacy
Effective date
Apr 29, 2026
We identified it
Jun 19, 2026
Days to comply
—

Summary

This is a reissue of an existing pharmacy policy for Eladocagene exuparvovec-tneq (Kebilidi™), a gene therapy treatment. The policy has been updated and will be reissued with an effective date of April 29, 2026.

Action Required

Action needed
No immediate action required. Monitor for the full policy details when they become available closer to the April 29, 2026 effective date to understand any coverage or billing changes for this specialty gene therapy medication.

Related policy hubs